Haematological Malignancies: News from ASH 2018

News and video reports on the research presented during ASH 2018 in San Diego

Video reports

Reporting from ASH 2018, Umberto Vitolo first discusses the results from the FLYER trial that explored de-escalation of standard treatment in young, low risk DLBCL patients. He also comments on results from everyday clinical practice in the US about CAR-T cell therapy, which are very similar with what has been observed in the clinical trials setting.


A large amount of interesting data in chronic lymphocytic leukaemia (CLL) were presented at ASH 2018. Alexander Egle reports on the results from the ALLIANCE trial studying ibrutinib alone or in combination, and several study results on CD19 CAR-T cell therapy.


Reporting from ASH 2018, Jonathan Peled explains that outcome variability after bone marrow transplantation could be impacted by pre-HCT microbiota injury. The analysis of the data and samples collected from this very large study showed that microbiota injury may be used as a predictor to adapt treatment decisions, and ultimately intervene directly at the microbiome level. ASH 2018 abstract:811


Highlights on rivaroxaban thromboprophylaxis in patients receiving anticancer therapyReporting from ASH 2018, Alok Khorana explains that patients with solid tumours or lymphoma, at high risk for developing a blood clot according to the Khorana score but without a blood clot already present were randomised to rivaroxaban thromboprophylaxis or control arm. Compliance was not good after a few months, but the analysis demonstrated a significant reduction of blood clots occurrence in the treatment arm. ... ASH 2018 abstract:LBA-1


Reporting from ASH 2018, Thierry Facon explains that the MAIA trial explored triplet therapy in elderly patients with newly diagnosed multiple myeloma ineligible for transplant.
The study met its primary endpoint, showing 15% difference in progression-free survival rate at 30 months. The response rate was also better in the daratumumab arm with a better quality of response as 24% of patients achieve MRD negative status. The safety profile was comparable with what has been observed in other daratumumab trials.
This combination should become the new standard of care in this group of patients.

medwireNews articles (ESMO members)

Ibrutinib Regimens Achieve ‘Superior’ PFS For Treatment-Naïve CLL in Older Patients

3 Dec 2018, Ibrutinib, with or without rituximab, improves progression-free survival for older patients with untreated chronic lymphocytic leukaemia compared with chemotherapy...
Read the article

High Response Rates With Tisagenlecleucel In Adult Refractory DLBCL Patients

4 Dec 2018, Phase II trial findings add support for the use of chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma...
Read the article

2-Year ZUMA-1 Results Add Support For Axicabtagene Ciloleucel In Refractory Large B-Cell Lymphoma

5 Dec 2018, Long-term follow-up of axicabtagene ciloleucel-treated patients with refractory large B-cell lymphoma suggests a role for the chimeric antigen receptor T-cell therapy in this setting...
Read the article

Shorter Chemotherapy Course Feasible For Younger DLBCL Patients

6 Dec 2018, Reducing CHOP chemotherapy to four cycles does not reduce efficacy for younger patients with favourable-prognosis diffuse large B-cell lymphoma...
Read the article

Genetic Mechanism Of Venetoclax Resistance In CLL Patients Identified

6 Dec 2018, The BCL2 Gly101Val mutation confers resistance to venetoclax treatment in chronic lymphocytic leukaemia patients...
Read the article